---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-083563"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-07-31T10:06:58+00:00"
generated_at: "2026-07-31T10:10:18.470868+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics confirms CVR terms: $30M milestone if FDA issues Priority Review Voucher for briquilimab by Dec 2028

## Summary
- Each share of common stock as of July 16, 2026 (closing date) receives one CVR.
- CVRs entitle holders to pro rata share of $30M if FDA issues Priority Review Voucher for briquilimab on or before Dec 31, 2028.
- If milestone achieved and change of control occurs, payment on earlier of change of control consummation or 90 days after monetization event.
- CVRs are non-transferable, not certificated, not registered with SEC, not listed on any exchange.
- CVRs continue if milestone achieved but monetization not yet occurred; payment due 90 days after monetization.

## SEC filing metadata
- accession: 0001213900-26-083563
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-07-31T10:06:58+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026083563/0001213900-26-083563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026083563/ea0299917-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-083563
- JSON: https://secwatch.observer/filing/0001213900-26-083563.json
- Plain text: https://secwatch.observer/filing/0001213900-26-083563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.